Novartis Creates New Model R&D Center in China

Novartis Creates New Model R&D Center in China

Business News Agency Nov. 19 News Recently, Novartis Pharmaceuticals of Switzerland announced its third-quarter financial report. The financial report showed that its third-quarter net profit rose to 2.319 billion US dollars from 2.112 billion US dollars in the same period last year, an increase of 10%. Third-quarter net sales increased by 13% year-on-year to US$12.6 billion. Among them, the cancer business sold 10 billion U.S. dollars in 2009, while the Chinese market accounted for only 1%, and there is great room for development.

Jiang Huayang, a researcher in the pharmaceutical industry at China Investment Advisors, pointed out that Novartis's performance in the third quarter has exceeded its expectations. Because its cancer business has broad prospects for development in China, Novartis Oncology plans to increase its capital by US$1 billion within five years. Shanghai's R&D center, which has always been at the "service headquarters," has expanded into the largest integrated R&D center in China that is directly researching from the front of drug development. This is also the biggest difference from other multinational pharmaceutical companies.

Jiang Huayang pointed out that at present, Novartis has headquarters of Novartis Research and Development Center in Basel, Switzerland, and Cambridge R&D center in Massachusetts. Novartis Pharmaceuticals has put all of its basic research, drug screening, new drug research and development and clinical research into R&D in Shanghai. After the center, Shanghai R&D Center will also become Novartis's third largest R&D center in the world. At that time, Novartis Shanghai Biomedical Research Institute will also become China's largest comprehensive R&D center.

Zhang Junlin, research director of China Investment Consulting Group, pointed out that since the new medical reform, more and more multinational pharmaceutical companies have entered China. Their main focus is on the 850 billion market opportunities and the growing demand for medical services in China. Although multinational pharmaceutical companies entering China undoubtedly seized part of the market share of pharmaceutical companies in China, they also brought advanced technologies, sound management experience, and considerate services. From this perspective, transnational pharmaceutical groups entered China is profitable. More than disadvantages.

The "Investment Analysis and Forecast Report of China's Pharmaceutical Industry 2010-2015" issued by China Investment Advisors pointed out that Novartis currently has four companies in Beijing and Shanghai, covering its patented drugs, generic drugs and eye care. , consumer health care, and animal health care. The Novartis Shanghai R&D Center also established contact with Fudan University. The two parties jointly established a joint research lab to share and learn about the world's leading pharmaceutical technologies.

Amber Sterile Serum Vials are primarily used for mixing different medications or solutions for injection or research applications like HCG, heparin, lidocaine, diabetic medications and morphine for intravenous or syringe injections. Finished vials can meet the FDA`s authorised 14-day sterility test.Amber Sterile Serum Vials are produced by aluminum caps, non-latex butyl stoppers and clear SCHOTT Neutral Type I glass vials. The production process of sterile Serum Vials is carried out under strict Class 100 workshop.

Amber Sterile Serum Vials

Amber Sterile Serum Glass Vials,Amber Serum Vials,Amber Glass Serum Vials

China Lemon Trading Co.,Ltd ,